Cited by 203HER2/EGFR in Cancer ResearchPI3K/AKT/mTOR signaling in cancerCancer Cells and Metastasis

The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.

Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies

Open access

Hanker, Ariella B., Pfefferle, Adam D., Balko, Justin M., Kuba, María Gabriela, Young, Christian D., Sánchez, Violeta, Sutton, Cammie R., Cheng, Hailing, Perou, Charles M., Zhao, Jean J., Cook, Rebecca S., Arteaga, Carlos L.·2013·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.1303204110PMC PMC3761610

Open this paper in CoChat — free account Open PDF

Abstract

Human epidermal growth factor receptor 2 (HER2; ERBB2) amplification and phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) mutations often co-occur in breast cancer. Aberrant activation of the phosphatidylinositol 3-kinase (PI3K) pathway has been shown to correlate with a diminished response to HER2-directed therapies. We generated a mouse model of HER2-overexpressing (HER2(+)), PIK3CA(H1047R)-mutant breast cancer. Mice expressing both human HER2 and mutant PIK3CA in the mammary epithelium developed tumors with shorter latencies compared with mice expressing either oncogene alone. HER2 and mutant PIK3CA also cooperated to promote lung metastases. By microarray analysis, HER2-driven tumors clustered with luminal breast cancers, whereas mutant PIK3CA tumors were associated with claudin-low breast cancers. PIK3CA and HER2(+)/PIK3CA tumors expressed elevated transcripts encoding markers of epithelial-to-mesenchymal transition and stem cells. Cells from HER2(+)/PIK3CA tumors more efficiently formed mammospheres and lung metastases. Finally, HER2(+)/PIK3CA tumors were resistant to trastuzumab alone and in combination with lapatinib or pertuzumab. Both drug resistance and enhanced mammosphere formation were reversed by treatment with a PI3K inhibitor. In sum, PIK3CA(H1047R) accelerates HER2-mediated breast epithelial transformation and metastatic progression, alters the intrinsic phenotype of HER2-overexpressing cancers, and generates resistance to approved combinations of anti-HER2 therapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1073/pnas.1303204110

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Gianni, L., Pieńkowski, T., Im, Y., Roman, L., Tseng, L., Liu, M.-C., Lluch, A. M., Starosławska, E., de la Haba-Rodríguez, J., Im, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70336-9 · Cited by 2,427
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
Prat, A., Parker, J. S., Karginova, O. A., Fan, C., Livasy, C., Herschkowitz, J. I., He, X., & Perou, C. M. (2010) · Breast Cancer Research · doi:10.1186/bcr2635 · Cited by 2,290
Self-citation
Generation of a functional mammary gland from a single stem cell
Shackleton, M., Vaillant, F., Simpson, K. J., Stingl, J., Smyth, G. K., Asselin-Labat, M.-L., Wu, L., Lindeman, G. J., & Visvader, J. E. (2006) · Nature · doi:10.1038/nature04372 · Cited by 2,005
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627
Molecular Definition of Breast Tumor Heterogeneity
Shipitsin, M. V., Campbell, L. L., Argani, P., Weremowicz, S., Bloushtain-Qimron, N., Yao, J., Nikolskaya, T., Serebryiskaya, T., Beroukhim, R., Hu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.01.013 · Cited by 1,347
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors
Herschkowitz, J. I., Simin, K. J., Weigman, V., Mikaelian, I., Usary, J., Hu, Z., Rasmussen, K., Jones, L. P., Assefnia, S., Chandrasekharan, S., et al. (2007) · Genome biology · doi:10.1186/gb-2007-8-5-r76 · Cited by 1,337
Self-citation
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Baselga, J. M., Bradbury, I., Eidtmann, H., Cosimo, S. D., de Azambuja, E., Aura, C. M., Gómez, H., Dinh, P., Fauria, K., Dooren, V. V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61847-3 · Cited by 1,324
Hedgehog Signaling and Bmi-1 Regulate Self-renewal of Normal and Malignant Human Mammary Stem Cells
Liu, S., Dontu, G., Mantle, I. D., Patel, S. H., Ahn, N.-S., Jackson, K. W., Suri, P., & Wicha, M. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0054 · Cited by 1,241

Show all 41 references

Sorted by citations

The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes
Pereira, B., Chin, S., Rueda, O. M., Vollan, H. K. M., Provenzano, E., Bardwell, H. A., Pugh, M., Jones, L. R., Russell, R., Sammut, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms11479 · Cited by 1,752
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048
Self-citation
The PI3K/AKT Pathway as a Target for Cancer Treatment
Mayer, I. A., & Arteaga, C. L. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-062913-051343 · Cited by 833
Self-citation
EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance
Uribe, M. L., Marrocco, I., & Yarden, Y. (2021) · Cancers · doi:10.3390/cancers13112748 · Cited by 604
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors
Vora, S. R., Juric, D., Kim, N., Mino-Kenudson, M., Huynh, T., Costa, C., Lockerman, E. L., Pollack, S. F., Liu, M., Li, X., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.020 · Cited by 438
PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment
Zotano, Á. G., Mayer, I. A., & Arteaga, C. L. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9637-x · Cited by 428
Self-citation
Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors
Millis, S. Z., Ikeda, S., Reddy, S. B., Gatalica, Z., & Kurzrock, R. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0891 · Cited by 326
Cancer-Associated PIK3CA Mutations in Overgrowth Disorders
Madsen, R. R., Vanhaesebroeck, B., & Semple, R. K. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.08.003 · Cited by 276
Breast Cancer Molecular Stratification
Russnes, H. G., Lingjærde, O. C., Børresen‐Dale, A., & Caldas, C. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.04.022 · Cited by 277
PIK3CA Mutations Are Associated With Lower Rates of Pathologic Complete Response to Anti–Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer
Loibl, S., von Minckwitz, G., Schneeweiß, A., Paepke, S., Lehmann, A., Rezai, M., Zahm, D. M., Sinn, H., Khandan, F., Eidtmann, H., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.7876 · Cited by 258
Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives
Vernieri, C., Milano, M., Brambilla, M., Mennitto, A., Maggi, C., Cona, M. S., Prisciandaro, M., Fabbroni, C., Celio, L., Mariani, G., et al. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.05.001 · Cited by 258
New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer
Yang, S. X., Polley, E. C., & Lipkowitz, S. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.03.004 · Cited by 240
PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials
Dey, N., De, P. K., & Leyland-Jones, B. R. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.037 · Cited by 237
Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer
Li, H., Prever, L., Hirsch, E., & Gulluni, F. (2021) · Cancers · doi:10.3390/cancers13143517 · Cited by 233
Efficacy of PI3K inhibitors in advanced breast cancer
Verret, B., Cortes, J., Bachelot, T., Andre, F., & Arnedos, M. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz381 · Cited by 221
Integrating Network Pharmacology and Pharmacological Evaluation for Deciphering the Action Mechanism of Herbal Formula Zuojin Pill in Suppressing Hepatocellular Carcinoma
Guo, W., Huang, J., Wang, N., Tan, H., Cheung, F., Chen, F., & Feng, Y. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01185 · Cited by 211
Synergy in activating class I PI3Ks
Burke, J. E., & Williams, R. L. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.12.003 · Cited by 216
Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up
Kadara, H. N., Choi, M., Zhang, J., Parra, E. R., Rodriguez‐Canales, J., Gaffney, S. G., Zhao, Z., Behrens, C., Fujimoto, J., Chow, C.-W. B., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw436 · Cited by 200
Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients
Chen, L., Liu, Y., Yao, L., Kuang, X.-Y., Zuo, W., Li, S., Qiao, F., Liu, Y., Cao, Z.-G., Zhou, S.-L., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03867-9 · Cited by 170
At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy
Vasan, N., & Cantley, L. C. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00633-1 · Cited by 172
In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer
Janiszewska, M., Liu, L., Almendro, V., Kuang, Y., Paweletz, C. P., Sakr, R. A., Weigelt, B., Hanker, A. B., Chandarlapaty, S., King, T. A., et al. (2015) · Nature Genetics · doi:10.1038/ng.3391 · Cited by 163
Self-citation
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer
Siravegna, G., Lazzari, L., Crisafulli, G., Bianchi, A. S., Mussolin, B., Cassingena, A., Martino, C., Lanman, R. B., Nagy, R. J., Fairclough, S. R., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.06.004 · Cited by 159
Co-Occurring Gain-of-Function Mutations in HER2 and HER3 Modulate HER2/HER3 Activation, Breast Cancer Progression, and HER2 Inhibitor Sensitivity
Hanker, A. B., Brown, B. P., Meiler, J., Marín, A., Jayanthan, H. S., Ye, D., Lin, C.-C. A., Akamatsu, H., Lee, K., Chatterjee, S., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2021.06.001 · Cited by 104
Self-citation
Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers
Subramanian, J., Katta, A., Masood, A., Vudem, D. R., & Kancha, R. K. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0845 · Cited by 105
Metabolic diversity within breast cancer brain-tropic cells determines metastatic fitness
Parida, P. K., Marquez-Palencia, M., Nair, V. R., Kaushik, A., Kim, K., Sudderth, J., Quesada-Diaz, E., Cajigas, Á., Vemireddy, V., Ericsson, P. I. G., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2021.12.001 · Cited by 102
Self-citation
Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer
Hanker, A. B., Estrada, M. V., Bianchini, G., Moore, P. D., Zhao, J., Cheng, F., Koch, J. P., Gianni, L., Tyson, D. R., Sanchez, V. M., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2808 · Cited by 102
Self-citation
HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
Hanker, A. B., Garrett, J. T., Estrada, M. V., Moore, P. D., Ericsson, P. I. G., Koch, J. P., Langley, E. J., Singh, S., Kim, P. S., Frampton, G. M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2287 · Cited by 96
Self-citation
P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer
Dillon, L. M., Bean, J. R., Yang, W., Shee, K., Symonds, L. K., Balko, J. M., McDonald, W. H., Liu, S., Gonzalez-Angulo, A. M., Mills, G. B., et al. (2014) · Oncogene · doi:10.1038/onc.2014.328 · Cited by 87
Self-citation
Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer
Ma, F., Guan, Y., Yi, Z., Chang, L., Li, Q., Chen, S., Zhu, W., Guan, X., Li, C., Qian, H., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32536 · Cited by 88
Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells
Rexer, B. N., Chanthaphaychith, S., Dahlman, K. B., & Arteaga, C. L. (2014) · Breast Cancer Research · doi:10.1186/bcr3601 · Cited by 80
Self-citation
Multivalent exposure of trastuzumab on iron oxide nanoparticles improves antitumor potential and reduces resistance in HER2-positive breast cancer cells
Truffi, M., Colombo, M., Sorrentino, L., Pandolfi, L., Mazzucchelli, S., Pappalardo, F., Pacini, C., Allevi, R., Bonizzi, A., Corsi, F., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-24968-x · Cited by 79
Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells
Canfield, K., Li, J., Wilkins, O. M., Morrison, M. M., Ung, M. H., Wells, W. A., Williams, C. R., Liby, K. T., Vullhorst, D., Buonanno, A., et al. (2015) · Cell Cycle · doi:10.4161/15384101.2014.994966 · Cited by 76
Self-citation
Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers
Sun, B., Mason, S., Wilson, R. C., Hazard, E. S., Wang, Y., Fang, R., Wang, Q., Yeh, E. S., Yang, M., Roberts, T. M., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0953-9 · Cited by 78
Self-citation
Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas
Ebbesen, S. H., Scaltriti, M., Bialucha, C. U., Morse, N., Kastenhuber, E. R., Wen, H. Y., Dow, L. E., Baselga, J. M., & Lowe, S. W. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1523693113 · Cited by 73
Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
Yi, Z., Rong, G., Guan, Y., Li, J., Chang, L., Li, H., Liu, B., Wang, W., Guan, X., Ouyang, Q., et al. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-00201-9 · Cited by 70
PI3K in stemness regulation: from development to cancer
Madsen, R. R. (2020) · Biochemical Society Transactions · doi:10.1042/bst20190778 · Cited by 69
Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis
Bertacchini, J., Guida, M., Accordi, B., Mediani, L., Martelli, A. M., Barozzi, P., Petricoin, E. F., Liotta, L. A., Milani, G., Giordan, M., et al. (2014) · Leukemia · doi:10.1038/leu.2014.123 · Cited by 69
Oncogenic PIK3CA promotes cellular stemness in an allele dose-dependent manner
Madsen, R. R., Knox, R. G., Pearce, W. P., López, S., Mahler-Araujo, B. M., McGranahan, N., Vanhaesebroeck, B., & Semple, R. K. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821093116 · Cited by 65
PIK3CAMutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
Rasti, A. R., Guimarães-Young, A., Datko, F. M., Borges, V. F., Aisner, D. L., & Shagisultanova, E. I. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00370 · Cited by 66
Mutation Variants and Co-Mutations as Genomic Modifiers of Response to Afatinib in HER2-Mutant Lung Adenocarcinoma
Fang, W., Zhao, S., Liang, Y., Yang, Y., Yang, L., Dong, X., Zhang, L., Shoufeng, W., Yang, Y., Yang, Y., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0547 · Cited by 63
Cancer stem cells and HER2 positive breast cancer: The story so far
Shah, D., & Osipo, C. (2016) · Genes & Diseases · doi:10.1016/j.gendis.2016.02.002 · Cited by 62
PIK3CA Mutational Status in Circulating Tumor Cells Can Change During Disease Recurrence or Progression in Patients with Breast Cancer
Markou, A. N., Farkona, S., Schiza, C., Efstathiou, T., Kounelis, S., Malamos, N., Georgoulias, V., & Lianidou, E. S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0149 · Cited by 61
Implications of stemness-related signaling pathways in breast cancer response to therapy
Angeloni, V., Tiberio, P., Appierto, V., & Daidone, M. G. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.08.004 · Cited by 61
Far Beyond the Usual Biomarkers in Breast Cancer: A Review
Pultz, B. D. A., da Luz, F. A. C., de Faria, P. R., Oliveira, A. P. L., de Araújo, R. A., & Silva, M. J. B. (2014) · Journal of Cancer · doi:10.7150/jca.8925 · Cited by 61
PI3K Inhibitors in Advanced Breast Cancer: The Past, The Present, New Challenges and Future Perspectives
Fuso, P., Muratore, M., D’Angelo, T., Paris, I., Carbognin, L., Tiberi, G., Pavese, F., Duranti, S., Orlandi, A., Tortora, G., et al. (2022) · Cancers · doi:10.3390/cancers14092161 · Cited by 55
Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer
Arienti, C., Zanoni, M., Pignatta, S., Río, A. D., Carloni, S., Tebaldi, M., Tedaldi, G., & Tesei, A. (2016) · Oncotarget · doi:10.18632/oncotarget.7575 · Cited by 54
The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistance
Zhang, Y. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107677 · Cited by 56
Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer*
Young, C. D., Zimmerman, L. J., Hoshino, D., Formisano, L., Hanker, A. B., Gatza, M. L., Morrison, M. M., Moore, P. D., Whitwell, C. A., Dave, B., et al. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m115.049783 · Cited by 53
Self-citation
PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer
Zhang, H., Zhang, L., He, Y., Jiang, D., Sun, J. L., Luo, Q., Liang, H., Wang, T., Li, F., Tang, Y., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217112 · Cited by 54
Identifying and targeting tumor-initiating cells in the treatment of breast cancer
Wei, W., & Lewis, M. T. (2015) · Endocrine Related Cancer · doi:10.1530/erc-14-0447 · Cited by 52
The Biological Roles and Clinical Applications of the PI3K/AKT Pathway in Targeted Therapy Resistance in HER2-Positive Breast Cancer: A Comprehensive Review
Zhong, H., Zhou, Z., Wang, H., Wang, R., Shen, K., Huang, R., & Wang, Z. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413376 · Cited by 50
Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data
Jagosky, M. H., & Tan, A. R. (2021) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s176514 · Cited by 56
HER2 in Solid Tumors: More than 10 Years Under the Microscope; where are we now?
Martin, V., Cappuzzo, F., Mazzucchelli, L., & Frattini, M. (2014) · Future Oncology · doi:10.2217/fon.14.19 · Cited by 48
PIK3CAH1047R and Her2 initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling
Cheng, H.-L., Liu, P.-X., Ohlson, C. E., Xu, E., Symonds, L., Isabella, A., Muller, W., Lin, N., Krop, I., Roberts, T., et al. (2015) · Oncogene · doi:10.1038/onc.2015.377 · Cited by 40
Self-citation
PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers
Wang, Q., Liu, P., Spangle, J. M., Von, T., Roberts, T. M., Lin, N., Krop, I. E., Winer, E. P., & Zhao, J. J. (2015) · Oncogene · doi:10.1038/onc.2015.406 · Cited by 46
Self-citation
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression
Schwarz, L. J., Hutchinson, K. E., Rexer, B. N., Estrada, M. V., Ericsson, P. I. G., Sanders, M. E., Dugger, T. C., Formisano, L., Zotano, Á. G., Red-Brewer, M., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx065 · Cited by 48
Self-citation
Targeting Cyclin D-CDK4/6 Sensitizes Immune-Refractory Cancer by Blocking the SCP3–NANOG Axis
Oh, S. J., Cho, H., Kim, S., Noh, K. H., Song, K., Lee, H.-J., Woo, S. R., Kim, S., Choi, C. H., Chung, J., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2325 · Cited by 45
A Novel Workflow to Enrich and Isolate Patient-Matched EpCAMhigh and EpCAMlow/negative CTCs Enables the Comparative Characterization of the PIK3CA Status in Metastatic Breast Cancer
Lampignano, R., Yang, L., Neumann, M., Franken, A., Fehm, T. N., Niederacher, D., & Neubauer, H. J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091885 · Cited by 45
First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2 -altered NSCLC: a retrospective real-world POLISH study
Yang, G., Yang, Y., Liu, R., Li, W., Xu, H., Hao, X., Li, J., Xing, P., Zhang, S., Ai, X., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221082339 · Cited by 44
Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease
Yarden, Y., & Wheeler, D. L. (2014) · Springer eBooks · doi:10.1007/978-1-4939-2053-2 · Cited by 44
PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma
Eze, N., Lee, J., Yang, D., Zhu, F., Neumeister, V. M., Sandoval-Schaefer, T., Mehra, R., Ridge, J. A., Forastiere, A. A., Chung, C. H., et al. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.02.026 · Cited by 40
The PI3K/mTOR inhibitor Gedatolisib eliminates dormant breast cancer cells in organotypic culture, but fails to prevent metastasis in preclinical settings
Shor, R. E., Dai, J., Lee, S., Pisarsky, L., Matei, I. R., Lucotti, S., Lyden, D. C., Bissell, M. J., & Ghajar, C. M. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13031 · Cited by 39
HER2 splice variants in breast cancer: investigating their impact on diagnosis and treatment outcomes
Hart, V., Gautrey, H., Kirby, J. A., & Tyson-Capper, A. J. (2020) · Oncotarget · doi:10.18632/oncotarget.27789 · Cited by 41
Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data
Armaghani, A. J., & Han, H. S. (2020) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s219436 · Cited by 38
Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
Cheng, X., Sun, Y., Highkin, M. K., Vemalapally, N., Jin, X., Zhou, B., Prior, J. L., Tipton, A. R., Li, S., Iliuk, A. B., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3558 · Cited by 38
Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas
Martín-Castillo, B., López‐Bonet, E., Cuyàs, E., Viñas, G., Pernas, S., Dorca, J., & Menéndez, J. A. (2015) · Oncotarget · doi:10.18632/oncotarget.6094 · Cited by 35
Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models
Belli, V., Matrone, N., Napolitano, S., Migliardi, G., Cottino, F., Bertotti, A., Trusolino, L., Martinelli, E., Morgillo, F., Ciardiello, D., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1230-z · Cited by 36
Precision Combination Therapies Based on Recurrent Oncogenic Coalterations
Li, X., Kong, E., Yan, G., Dereli, Z., Bozorgui, B., Imanirad, P., Elnaggar, J. H., Luna, A., Menter, D. G., Pilie, P. G., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0832 · Cited by 34
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
Gu, Y., Gao, H., Zhang, H., John, A. J., Zhu, X., Shivaram, S., Yu, J., Weinshilboum, R. M., & Wang, L. (2022) · Oncogene · doi:10.1038/s41388-022-02415-6 · Cited by 35
A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA -Mutated HER2-Positive Metastatic Breast Cancer
Jhaveri, K. L., Drago, J. Z., Shah, P. D., Wang, R., Pareja, F. G., Ratzon, F., Iasonos, A. E., Patil, S. N., Rosen, N. X., Fornier, M. N., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0047 · Cited by 34
Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms
Shi, H., Zhang, W., Zhi, Q., & Jiang, M. (2016) · Tumor Biology · doi:10.1007/s13277-016-5467-2 · Cited by 36
A SNAI2-PEAK1-INHBA stromal axis drives progression and lapatinib resistance in HER2-positive breast cancer by supporting subpopulations of tumor cells positive for antiapoptotic and stress signaling markers
Hamalian, S., Güth, R., Runa, F., Sanchez, F., Vickers, E., Agajanian, M. J., Molnar, J., Nguyen, T. M., Gamez, J., Humphries, J. D., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01906-2 · Cited by 32
Identification of novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy
Creedon, H., Gómez-Cuadrado, L., Tarnauskaitė, Ž., Balla, J., Canel, M., MacLeod, K. G., Serrels, B., Fraser, C., Unciti‐Broceta, A., Tracey, N., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7317 · Cited by 33
Anti-tumor efficacy of BEZ235 is complemented by its anti-angiogenic effects via downregulation of PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancers.
Dey, N., Sun, Y., Carlson, J. H., Wu, H., Lin, X., Leyland-Jones, B. R., & De, P. K. (2016) · PubMed · Cited by 31
Positive correlation between transcriptomic stemness and PI3K/AKT/mTOR signaling scores in breast cancer, and a counterintuitive relationship with PIK3CA genotype
Madsen, R. R., Erickson, E. C., Rueda, O. M., Robin, X., Caldas, C., Toker, A., Semple, R. K., & Vanhaesebroeck, B. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009876 · Cited by 33
An Integrative Analysis of PIK3CA Mutation, PTEN, and INPP4B Expression in Terms of Trastuzumab Efficacy in HER2-Positive Breast Cancer
Sueta, A., Yamamoto, Y., Yamamoto‐Ibusuki, M., Hayashi, M., Takeshita, T., Yamamoto, S., & Iwase, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0116054 · Cited by 30
Targeting Receptor Tyrosine Kinases in Cancer
Köstler, W. J., & Zielinski, C. C. (2014) · Springer eBooks · doi:10.1007/978-1-4939-2053-2_10 · Cited by 26
Clinical applications of mouse models for breast cancer engaging HER2/neu
Fry, E. A., Taneja, P., & Inoue, K. (2016) · Integrative Cancer Science and Therapeutics · doi:10.15761/icst.1000210 · Cited by 27
Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors
Abramson, V. G., Supko, J. G., Ballinger, T. J., Cleary, J. M., Hilton, J. F., Tolaney, S. M., Chau, N. G., Cho, D. C., Pearlberg, J., Lager, J. J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1764 · Cited by 29
Self-citation
Targeting the Breast Cancer Kinome
Miller, S. M., Goulet, D. R., & Johnson, G. L. (2016) · Journal of Cellular Physiology · doi:10.1002/jcp.25427 · Cited by 27
Synergistic interactions with PI3K inhibition that induce apoptosis
Zwang, Y., Jonas, O. H., Chen, C., Rinne, M. L., Doench, J. G., Piccioni, F., Tan, L., Huang, H., Wang, J., Ham, Y. J., et al. (2017) · eLife · doi:10.7554/elife.24523 · Cited by 28
Evaluating the immunologically “cold” tumor microenvironment after treatment with immune checkpoint inhibitors utilizing PET imaging of CD4 + and CD8 + T cells in breast cancer mouse models
Lu, Y., Houson, H. A., Gallegos, C., Mascioni, A., Jia, F., Aivazian, A., Song, P. N., Lynch, S. E., Napier, T. S., Mansur, A., et al. (2024) · Breast Cancer Research · doi:10.1186/s13058-024-01844-3 · Cited by 27
Self-citation
Novel treatment strategies for patients with HER2‑positive breast cancer who do not benefit from current targeted therapy drugs (Review)
Jiang, N., Lin, J., Wang, J., Zhang, B., Li, A., Chen, Z., Guo, S., Li, B., Duan, Y., Yan, R., et al. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6459 · Cited by 27
PIK3CA mutations and their response to neoadjuvant treatment in early breast cancer: A systematic review and meta‐analysis
Fan, H., Li, C., Xiang, Q., Xu, L., Zhang, Z., Liu, Q., Zhang, T., Zhou, Y. F., Zhao, X., & Cui, Y. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12618 · Cited by 28
Comparison of PIK3CA Mutation Prevalence in Breast Cancer Across Predicted Ancestry Populations
Chen, J. W., Murugesan, K., Newberg, J. Y., Sokol, E. S., Savage, H. M., Stout, T. J., Maund, S. L., & Hutchinson, K. E. (2022) · JCO Precision Oncology · doi:10.1200/po.22.00341 · Cited by 26
Pharmacogenomic and molecular docking studies on the cytotoxicity of the natural steroid wortmannin against multidrug-resistant tumor cells
Kuete, V., Saeed, M. E. M., Kadioglu, O., Börtzler, J., Khalid, H., Greten, H. J., & Efferth, T. (2014) · Phytomedicine · doi:10.1016/j.phymed.2014.11.011 · Cited by 26
Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial
Huang, L., Chen, S., Yang, W., Xu, B., Huang, T., Yang, H., Zheng, H. Y., Wang, Y., Song, E., Zhang, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4337 · Cited by 23
PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition
McNeill, R. S., Stroobant, E. E., Smithberger, E., Canoutas, D. A., Butler, M. K., Shelton, A., Patel, S. D., Limas, J. C., Skinner, K., Bash, R., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200014 · Cited by 25
Mouse Models for Exploring the Biological Consequences and Clinical Significance of PIK3CA Mutations
Mitchell, C. B., & Phillips, W. A. (2019) · Biomolecules · doi:10.3390/biom9040158 · Cited by 24
Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine
Hurvitz, S. A., Sadeghi, S., & Olevsky, O. M. (2014) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s47524 · Cited by 24
Current status of the prognostic molecular biomarkers in breast cancer: A systematic review
Kutomi, G., Mizuguchi, T., Satomi, F., Maeda, H., Shima, H., Kimura, Y., & Hirata, K. (2017) · Oncology Letters · doi:10.3892/ol.2017.5609 · Cited by 23
PIK3CA mutations in HER2-positive breast cancer: an ongoing conundrum
Goel, S., & Krop, I. E. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw246 · Cited by 22
Advances in the Application of Radionuclide-Labeled HER2 Affibody for the Diagnosis and Treatment of Ovarian Cancer
Hu, X., Li, D., Fu, Y.-J., Zheng, J., Feng, Z., Cai, J., & Wang, P. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.917439 · Cited by 21
Embryonic Lethality in Homozygous Human Her-2 Transgenic Mice Due to Disruption of the Pds5b Gene
Yong, C. S. M., Sharkey, J., Duscio, B., Venville, B., Wei, W., Jones, R. F., Slaney, C. Y., Arnau, G. M., Papenfuss, A. T., Schröder, J., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0136817 · Cited by 21
Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers
Young, C. D., Arteaga, C. L., & Cook, R. S. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0656-2 · Cited by 22
Self-citation
The Tyrosine Kinome Dictates Breast Cancer Heterogeneity and Therapeutic Responsiveness
Ha, J. R., Siegel, P. M., & Ursini‐Siegel, J. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25561 · Cited by 20
PtdIns(3,4,5)P 3 -dependent Rac exchanger 1 (P-Rex1) promotes mammary tumor initiation and metastasis
Srijakotre, N., Liu, H.-J., Nobis, M., Man, J., Yip, H. Y. K., Papa, A., Abud, H. E., Anderson, K. I., Welch, H. C. E., Tiganis, T., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2006445117 · Cited by 20
Association of PIK3CA mutation with outcomes in HER2-positive breast cancer treated with anti-HER2 therapy: A meta-analysis and bioinformatic analysis of TCGA‑BRCA data
Chen, H., Hu, X., Wang, D., Wang, Y., Yu, Y., & Yao, H. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101738 · Cited by 20
Precision medicine and personalized breast cancer: combination pertuzumab therapy
Dizon, D. S., Reynolds, K., Sarangi, S., & Bardia, A. (2014) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s37100 · Cited by 20
Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA
Garay, J. P., Smith, R. L., Devlin, K. L., Hollern, D. P., Liby, T. A., Liu, M., Boddapati, S. P., Watson, S. S., Esch, A. M., Zheng, T., et al. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01457-0 · Cited by 19

Authors: Hanker, A. B., Pfefferle, A. D., Balko, J. M., Kuba, M. G., Young, C. D., Sánchez, V., Sutton, C. R., Cheng, H., Perou, C. M., Zhao, J. J., Cook, R. S., & Arteaga, C. L.
Affiliations: Departments of aMedicine,
Departments of bPathology and Laboratory Medicine and
Vanderbilt University (US)
Pathology, and
Departments of eCancer Biology and
University of North Carolina at Chapel Hill (US)
Harvard University (US)
ORCID: Hanker, Ariella B.
Pfefferle, Adam D.
Balko, Justin M.
Young, Christian D.
Perou, Charles M.
Zhao, Jean J.
Cook, Rebecca S.
Arteaga, Carlos L.
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 2013-08-12
Volume: 110
Issue: 35
Pages: 14372-14377
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.1303204110
PMC: PMC3761610
OpenAlex: W2056427943
Cited by: 203
References: 41
Citations by year: 2026: 6 · 2025: 9 · 2024: 15 · 2023: 21 · 2022: 16 · 2021: 16 · 2020: 13 · 2019: 17 · 2018: 11 · 2017: 11 · 2016: 23 · 2015: 22 · 2014: 23
FWCI: 12.15
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
UNC Libraries
Funders: U.S. Department of Defense
Breast Cancer Research Foundation
Entertainment Industry Foundation (SU2C-AACR-DT0209)
Vanderbilt University
Vanderbilt-Ingram Cancer Center (P30 CA 68485)
National Institutes of Health (5r01ca138255-03)
Stand Up To Cancer (SU2C‐AACR‐DT0209)
National Cancer Institute (P50 CA98131, R01CA-138255, R01 CA80195, P30 CA 68485, CA148761, R01CA143126, R01CA080195, R01CA134502, R01CA172461, CA138255, P50CA098131, P50 CA 58223, P30CA068485, P50CA058223, R01CA148761)
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords: PIK3CA mutation, HER2 overexpression, breast cancer, PI3K signaling, trastuzumab resistance, lapatinib, pertuzumab, combination therapy resistance, mammosphere formation, epithelial-mesenchymal transition, claudin-low breast cancer, luminal breast cancer, lung metastasis, mammary tumors, PI3K inhibitors, mouse tumor model
MeSH terms: Animals, Antineoplastic Combined Chemotherapy Protocols, Lung Neoplasms, Mammary Neoplasms, Experimental, Mice, Transgenic, Mutation, Genes, erbB-2, Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, Mice, Class I Phosphatidylinositol 3-Kinases, Epithelial-Mesenchymal Transition

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks